Reports Q3 revenue $0, consensus $56.92M. Aggregate cash and cash equivalents and short-term investments were $238.6M and $412.3M at September 30, 2025 and December 31, 2024, respectively.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Ivonescimab’s Promising Trial Results Reinforce Buy Rating for Summit Therapeutics
- Summit Therapeutics price target raised to $40 from $35 at Citi
- Summit announces ivonescimab, chemo showed improvement in primary endpoint
- Summit Therapeutics PLC (SMMT) Q3 Earnings Cheat Sheet
- Summit Therapeutics announces expansion of Phase III program of ivonescimab